Semaglutide changes the appetite conversation.
Semaglutide has real human weight-loss results. Reading those alongside the unwanted effects makes the conversation more useful.
Appetite, weight and the rest of the story.
Semaglutide is the ingredient in Wegovy and Ozempic. It acts like GLP-1, a hormone released after eating that helps regulate appetite and blood sugar. That gives us a clearer job description than “boosts metabolism.”
Use
an appetite signal
Semaglutide helps reduce food intake. That is central to its weight-management role in Wegovy’s prescribing information. Less hunger is a specific effect. It doesn’t tell us someone will have more energy, build muscle or feel better in every other way.
We find it easier to follow the research when we name the job first. Appetite is a good place to be precise.
Store
the weight result in context
In STEP 1, adults without diabetes received a weekly semaglutide injection or a dummy injection. They had obesity, or overweight plus a weight-related condition. Average weight loss was about 15% with semaglutide and about 2% with the dummy treatment over 68 weeks. Both groups had lifestyle support.
That is a meaningful human result. It is also an average, not a forecast for you. A change in total body weight isn’t the same measurement as a change in body fat.
Respond
to unwanted effects too
Nausea, vomiting, diarrhea and constipation are among the common side effects in the label. Gallbladder problems also matter. The label’s strongest warning concerns thyroid tumors seen in rodents; whether that happens in people is unknown.
The label rules out use with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or MEN 2, an inherited hormone disorder. A benefit discussion needs room for these limits.
A weight result can’t answer every health question.
In SELECT, semaglutide lowered the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke versus a dummy treatment. Participants were 45 or older, had established heart or blood-vessel disease and overweight or obesity, and didn’t have diabetes. The events were counted together; this doesn’t establish a separate reduction in each. It isn’t a general promise of better health.
The product and the reason both matter.
Wegovy and Ozempic share semaglutide but have different approved uses. Weight management is one of Wegovy’s uses; type 2 diabetes is one of Ozempic’s. Both have other uses for particular groups. The exact product, form and health problem matter in a prescribing conversation.
A pharmacy-made preparation of semaglutide, called a compounded medicine, has no FDA approval. A brand medicine’s approval doesn’t extend to it. Our comparison explains the evidence; a clinician has to consider your circumstances.